Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease

Richard C. Becker; John Alexander; Christopher K. Dyke; Robert A. Harrington

doi:10.1160/TH04-05-0289

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2004; 92(06): 1182-1193
DOI: 10.1160/TH04-05-0289

Theme Issue Article

Schattauer GmbH

Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease

Authors

Richard C. Becker

¹Duke Cardiovascular Thrombosis Center, Duke University Medical Center, Durham, North Carolina, USA

²Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
John Alexander

¹Duke Cardiovascular Thrombosis Center, Duke University Medical Center, Durham, North Carolina, USA

²Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
Christopher K. Dyke

¹Duke Cardiovascular Thrombosis Center, Duke University Medical Center, Durham, North Carolina, USA

²Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
Robert A. Harrington

¹Duke Cardiovascular Thrombosis Center, Duke University Medical Center, Durham, North Carolina, USA

²Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA

Abstract

Summary

The development of anticoagulants for treating patients with atherothrombotic disorders of the arterial circulatory system has focused, either directly or indirectly, on thrombin – a pleuripotential effector enzyme with prothrombotic and proinflammatory properties. The pivotal role of factor (f) Xa in thrombin generation, coupled with its direct cellular effects and widely recognized limitations of currently available anticoagulants, has led to the development of pharmacologic inhibitors of this important protease. The following review focuses on DX9065a – first in a class of direct, selective and reversible fXa antagonists – and its potential applications in the management of patients with cardiovascular disease.

Keywords

DX-9065a - Factor Xa - antagonist

Full Text

References

References
1 Hoffman M, Monroe III DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-65.
2 Mutch NJ, Robbie LA, Booth NA. Human thrombi contain an abundance of active thrombin. Thromb Haemost 2001; 86: 1028-34.
3 Barry W, Gimple LW, Humphries JE. et al. Arterial thrombin activity after angioplasty in an atherosclerotic rabbit model. Time course and effect of hirudin. Circulation 1996; 94: 88-93.
4 Mutch NJ, Robbie LA, Booth NA. Human thrombi contain an abundance of active thrombin. Thromb Haemost 2001; 86: 1028-34.
5 Banyai I, Varadi A, Pathy L. Common evolutionary origin of the fibrin-binding structures of fibronectin and tissue-type plasminogen activator. FEBS Letters 1983; 163: 37-41.
6 Doolittle RF, Feng DF, Johsnon MS. Computer-based characterization of epidermal grown factor precursor. Nature 1984; 307: 558-60.
7 DiScipio RG, Hermodson MA, Davie EW. Activation of human factor X (Stuart factor) by a protease from Russell’s viper venom. Biochemistry 1977; 16: 5253-60.
8 Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Semin Hematol 1992; 29: 213-26.
9 Bar-Shavit R, Eldor A, Vlodavsky I. Binding of thrombin to sub-endothelial extracellular matrix. Protection and expression of functional properties. J Clin Invest 1989; 84: 1096-14.
10 Huber R. Automated convolution molecule method. Acta Crystollogra 1965; 19: 353-6.
11 Bono F, Herault JP, Avril C. et al. Human umbilical vein endothelial cells express high affinity receptors for factor Xa. J Cellular Physiol 1997; 172: 36-43.
12 Herbert J, Bono F, Herault J. et al. Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo . J Clin Invest 1998; 101: 993-1000.
13 Scheffer P, Mares AM, Bono F. et al. Coagulation factor Xa induces endotheliumdependent relaxations in rat aorta. Circ Res 1997; 81: 824-8.
14 Herault J-P, Bono F, Avril C. et al. Activation of human vascular endothelial cells by factor Xa effect of specific inhibitors. Biochem Pharmacol 1999; 27: 603-10.
15 Pejler G, Lunderius C, Tomasini-Johansson B. Macrophages synthesize factor X and secrete factor X/Xa-containing prothrombinase activity into the surrounding medium. Thromb Haemost 2000; 84: 429-35.
16 Schwartz RS, Holder DJ, Holmes DR. et al. Neointimal thickening after severe coronary artery injury is limited by short-term administrations of a factor Xa inhibitor: results in a porcine model. Circulation 1996; 93: 1542-8.
17 Damiano BP, D’Andrea MR, de Garavilla L. et al. Increased expression of protease activated receptro-2 (PAR-2) in balloon-injured rat carotid artery. Thromb Haemost 1999; 81: 808-14.
18 Bretschneider E, Braun M, Fischer A. et al. Factor Xa acts as a PDGF-independent mitogen in human vascular smooth muscle cells. Thromb Haemost 2000; 84: 499-505.
19 Altieri DC, Edgington TS. Identification of effector cell protease receptor-1. A leukocyte distributed receptor for the serine protease factor Xa. J Immunol 1990; 145: 246-53.
20 Plescia J, Altieri DC. Activation of Mac-1 (CD11B/CD18)-bound factor X by released cathepsin G defines an alternative pathway of leucocyte initiation of coagulation. Biochem J 1996; 319 (03) 873-9.
21 Cirino G, Cicala C, Bucci M. et al. Factor Xa as interface between coagulation and inflammation: molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo. J Clin Invest 1997; 99: 2446-51.
22 Bajaj MS, Birktoft JJ, Steer SA. et al. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 959-72.
23 Bajaj MS, Kuppuswamy MN, Manepalli AN. et al. Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues. Thromb Haemost 1999; 82: 1047-52.
24 Grabowski EF, Reininger AJ, Petteruti PG. et al. Shear stress decreases endothelial cell tissue factor activity by augmenting secretion of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2001; 21: 157-62.
25 Lupu C, Lupu F, Dennehy U. et al. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1995; 15: 2055-62.
26 McGee MP, Foster S, Wang X. Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes. A potential mechanism for localized control of blood coagulation. J Exp Med 1994; 179: 1847-54.
27 Becker RC, Spencer FA, Li YF. et al. Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes. J Am Coll Cardiol 1999; 34: 1020-27.
28 Katakura S, Nagahara T, Hara T. et al. Molecular model of an interaction between factor Xa and DX-9065a, a novel factor Xa inhibitor: contribution of the acetimidoylpyrrolidine moiety of the inhibitor to potency and selectivity for serine proteases. Eur J Med Chem 1995; 30: 387-94.
29 Katakura SI, Nagahara T, Hara T. et al. A novel factor Xa inhibitor: Structure-activity relationships and selectivity between factor Xa and thrombin. Biochem Biophys Res Commun 1993; 197: 965-72.
30 Stubbs MT, Huber R, Bode W. Crystal structures of factor Xa specific inhibitors in complex with trypsin: structural grounds for inhibition of factor Xa and selectivity against thrombin. FEBS Letters 1995; 375: 103-7.
31 Brandstetter H, Kühne A, Bode W. et al. X-ray structure of active site-inhibited clotting factor Xa: Implications for drug design and substrate recognition. J Biol Chem 1996; 271: 29988-92.
32 Ishihara H, Hara T, Kunitada S. Antithrombin III independent mechanism of factor Xa inhibition on prothrombinase with DX-9065a. Thromb Haemost 1996; 26 (Suppl. 03) 580.
33 Hërault JP, Bernat A, Pflieger AM. et al. Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. JPET 1997; 283: 16-22.
34 Rezaie AR. DX-9065a inhibition of factor Xa and the prothrombinase complex: Mechanism of inhibition and comparison with therapeutic heparins. Thromb Haemost 2003; 89: 112-21.
35 Niemetz J, Fallon JT, Harrington E. et al. Rapid generation of thrombin by atheroma and platelets. J Thromb Haemost 2004; 02: 321-6.
36 Yamaguchi Y, Okabe K, Liang J. et al. Thrombin and factor Xa enhance neutrophil chemoattractant production after ischemia/ reperfusion in the rat liver. K Surg Res 2000; 92: 96-102.
37 Yamaguchi Y, Okabe J, Liang J. et al. A synthetic selective inhibitor of factor Xa DX-9065a, reduces monocyte chemoattractant protein-1 expression after ischemia-reperfusion injury in rat liver. Dig Dis Sci 1999; 44: 2568-76.
38 Kaiser B, Paintz M, Scholz O. et al. A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rates. Thromb Res 2000; 98: 175-85.
39 Nakata M, Kenekura S, Maruyama I. DX-9065a, an Xa inhibitor, inhibits prothrombininduced A549 lung adenocarcinoma cell proliferation. Cancer Letter 1998; 122: 127-33.
40 Herbert JM, Dol BF, Hérault P. et al. DX-9065a, a novel, synthetic, selective and orally active inhibitor of factor Xa: In vitro and in vivo studies. JPET 1996; 276: 1030-8.
41 Yamazaki M, Asakura H, Aoshima K, Saito M. et al. Protective effects of Dx-9065a, an orally active novel synthesized and selective inhibitor of factor Xa, against thromboplastininduced experimental disseminated intravascular coagulation in rats. Semin Thromb Hemost 1996; 22: 255-9.
42 Hara T, Yokoyama A, Tanabe K. et al. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost 1995; 74: 635-9.
43 Yamashita T, Matsuoka A, Giddings JC. et al. The antithrombotic effect of synthetic low molecular weight human factor Xa inhibitor, DX-9065a, on HE-NE laser-induced thrombosis in rat mesenteric microvessels. Thromb Res 1997; 85: 45-51.
44 Kim DI, Kambayashi JI, Shibuya T. et al. In vivo evaluation of DX-9065a, a synthetic factor Xa inhibitor, in experimental vein graft. J Atheroscler Thromb 1996; 02: 110-16.
45 Yokoyama T, Kelly AB, Marzec UM. et al. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates. Circulation 1995; 92: 485-91.
46 Hara T, Yokoyama A, Morishima Y. et al. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb Res 1995; 80: 99-104.
47 Hara T, Yokoyma A, Ishihara H. et al. DX-9065a, a new synthetic, patient anticoagulant and selective inhibitor of factor Xa. Thromb Haemost 994: 71: 314-19.
48 Morishima Y, Tanabe K, Terada Y. et al. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor, comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb Haemost 1997; 78: 1366-77.
49 Ieko M, Tarumi T, Takeda M. et al. Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis. J Thromb Haemost 2004; 02: 612-18.
50 Murayama N, Tanaka M, Kunitada S. et al. Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers. Clin Pharm Ther 1999; 66: 258-64.
51 Murayama N, Tanaka S, Kikuchi T. et al. Radioimmunoassay method for DX-9065a, an anticoagulant agent. Development, evaluation and application to human plasma. JPBA 1996; 14: 1435-45.
52 Marayama N, Sudo KI. High performance liquid chromoatographic method for determination of DX-9065a, a novel anticoagulant, in human urine and feces using cation-exchange solid-phase extraction. J Chromatography B 1997; 693: 389-96.
53 Shimbo D, Osende J, Chen J. et al. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor. A comparative study in humans vs low molecular weight heparin. Thromb Haemost 2002; 88: 733-8.
54 Depasse F, Caplain H, Kunitada S. et al. Assessment of the pharmacodynamic profile of DX-9065a, a direct factor Xa inhibitor, in 36 healthy male subjects: A first study using subcutaneous route. Thromb Haemost Suppl. July 2001: P3098.
55 Dyke CK, Becker RC, Kleiman NS. et al. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation 2002; 105: 2385-91.
56 Becker RC, Bovill EG, Dyke CK. et al. Response in plasma-based coagulation measurements to DX-9065a, a novel factor Xa inhibitor, infused in patients with stable coronary artery disease. Thromb Haemost Suppl. July 2001: P3096.
57 Alexander JH, Becker RC, Hasselblad V. et al. Effect of the direct factor Xa inhibitor, DX9065a, on thrombin generation in patients with stable coronary artery disease. Thromb Haemost. 2001: P2017.
58 Bovill EG, Becker RC, Dyke CK. et al. Functional anti-Xa assay correlates highly with direct measurement of a novel factor Xa inhibitor, DX-9065a, in the XaNADU Phase 1B dose finding study. Thromb Haemost Suppl. July 2001: P3096.
59 Depasse F, Samama MM. Measurement of anti-Xa activity of direct factor Xa inhibitors: Inter-assay variability for Dx-9065a. Thromb Haemost Suppl. July 2001: P687.
60 Dyke CK, Becker RC, Bovill EG. et al. Doseresponsible relationship of a point-of-care PT/INR to the novel factor Xa inhibitor DX9065a in patients with coronary artery disease: Results from XaNADU Phase 1B. Thromb Haemost Suppl. July 2001 Abstract CD3614..
61 Alexander JH, Dyke CK, Yang H. et al. Initial experience with Factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot. J Thromb Haemost 2004; 02: 234-341.
62 Alexander JH, Yang H, Becker RC. et al. Direct, selective, factor Xa inhibition in patients with Non-ST-Elevation acute coronary syndromes from the United States, Canada, and Japan: Results of the XaNADUACE Trial. Thromb Haemost. 2004 in press..